Akèy › Maladi Alzheimer › New Jersey
Etid klinik pou Maladi Alzheimer nan New Jersey
25 etid pou Maladi Alzheimer ap chèche patisipan nan sit nan New Jersey.
Vil nan New Jersey
Tèks ofisyèl etid la (Anglè)
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Clinical Site, West Long Branch
Ap rekriteFaz 2
Laj 55 a 90 · Tout sèks · Mizajou Sep 30, 2026 · NCT06887192A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Bio Behavioral Health, Toms River
Ap rekriteFaz 2
Laj 55 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06540833A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Local Institution - 1664, Princeton
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 28, 2026 · NCT06937229A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
- The Cognitive and Research Center of New Jersey - Springfield- Site Number : 8400005, Springfield
Ap rekriteFaz 2
Laj 55 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT07688213A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Advanced Memory Research Institute - CenExel - PPDS, Toms River
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT06585787Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
- CenExel Research - Toms River, Toms River
Ap rekriteFaz 2
Laj 55 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06847321Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- The Cognitive and Research Center of New Jersey, Ridgewood
- The Cognitive and Research Center of New Jersey, Springfield
Ap rekriteFaz 3
Laj 50 a 90 · Tout sèks · Mizajou Sep 21, 2026 · NCT07177352Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons
- Kessler Foundation, East Hanover
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05048966A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- The Cognitive and Research Center of New Jersey, Springfield
- Advanced Clinical Institute, West Long Branch
Ap rekriteFaz 3
Laj 60 a 85 · Tout sèks · Mizajou Sep 17, 2026 · NCT06976203Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
- Hackensack Medical Center, Hackensack
Ap rekrite
Laj 50 a 100 · Tout sèks · Mizajou Sep 17, 2026 · NCT05295615A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
- Eisai Trial Site #1, Nutley
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 16, 2026 · NCT07821658A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Global Medical Institutes LLC; Princeton Medical Institute, Princeton
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 16, 2026 · NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Local Institution - 2650, Toms River
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 16, 2026 · NCT07011745Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Local Institution - 0059, Livingston
- Local Institution - 0081, Toms River
Ap rekriteFaz 2
Laj 55 a 90 · Tout sèks · Mizajou Sep 1, 2026 · NCT06808984A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064), Ridgewood
- The Cognitive and Research Center of NJ ( Site 1057), Springfield
- CenExel- AMRI ( Site 1018), Toms River
Ap rekriteFaz 2
Laj 50 a 85 · Tout sèks · Mizajou Aug 26, 2026 · NCT07033494A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- CenExel AMRI, Toms River
Ap rekriteFaz 1
Laj 50 a 85 · Tout sèks · Mizajou Aug 24, 2026 · NCT06297590A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Advanced Memory Research Institute of New Jersey, Toms River
Ap rekriteFaz 3
Laj 60 a 85 · Tout sèks · Mizajou Aug 20, 2026 · NCT06976216Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Rutgers-Robert Wood Johnson Medical School, New Brunswick
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 4, 2026 · NCT06563895A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- The Cognitive and Research Center of New Jersey, Springfield
Ap rekriteFaz 3
Laj 55 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07602582A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- CenExel-HRI, Marlton
Ap rekriteFaz 1Volontè an sante akeyi
Laj 45 a 85 · Tout sèks · Mizajou Jun 4, 2026 · NCT06657768A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
- Eisai Trial Site #1, Nutley
Ap rekriteEtid obsèvasyon
Laj 19 ak plis · Tout sèks · Mizajou Apr 21, 2026 · NCT06810960Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
- Nuclear Imaging Institute, Englewood
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 120 · Tout sèks · Mizajou Apr 13, 2026 · NCT07012993Exercise to Improve Brain Health in Older African Americans
- Rutgers, The State University of New Jersey - Newark campus, Newark
Ap rekriteFaz 2Volontè an sante akeyi
Laj 60 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT05597124ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
- Rutgers - Institute for Health, New Brunswick
Ap rekriteFaz 2Volontè an sante akeyi
Laj 60 ak plis · Tout sèks · Mizajou Feb 6, 2026 · NCT07392723Open-label Extension Study in Participants With Early Alzheimer's Disease
- GSK Investigational Site, Toms River
Ap rekriteFaz 2
Laj 50 a 85 · Tout sèks · Mizajou Feb 2, 2026 · NCT07105709Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.